贺普丁与甘利欣对慢性乙型肝炎免疫调节作用的对比

The Analysis of immuno-regulation with lamivudine and diammonium glycyrrhizinate in the Treatment of Chronic Hepailtis B

目的对比观察贺普丁与甘利欣治疗慢性乙型肝炎的疗效。方法将本院收治的90例慢性乙型肝炎患者随机分成2组,每组45例。A组为口服贺普丁(拉米夫定)0.1g,1次/d;B组为口服甘利欣胶囊150mg,3次/d;治疗6个月后观察HBeAg/抗-HBe血清转换率及HBV-DNA阴转率。结果A组的CD4百分比为47.35.5(%),CD8百分比为34.92.9(%);B组分别为35.54.8(%)和27.13.2(%)。两组之间的差异具有统计学意义(P值均<0.05)。结论贺普丁(拉米夫定)较甘利欣治疗慢性乙型肝炎,具有更为肯定的效果,对于免疫调节有更为积极的作用。

Objective To observe the immuno-regulation effects of lamivudine and diammonium to treat chronic hepatitis B. Methods 90 chronic hepatitis B patients were enrolled and randomized into the group A（treat with lamivudine） and the group B（treat with diammonium glycyrrhizinate）. Results The rate of CD4 and CD8 in group A were superior to those in group B （47. 3 5.5% ,34. 9 2.9% ;35.5 4. 8% ,27. 1 3.2% ） Conclusion The effects of treatment for the lamivudine to treat chronic hepatitis B is better is better than diammonium glyeyrrhizinate.